https://www.yiliao.com/index.php?action=history&feed=atom&title=IDH1
IDH1 - 版本历史
2026-04-21T09:46:29Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=IDH1&diff=311613&oldid=prev
2025年12月29日 (一) 11:47 77921020
2025-12-29T11:47:44Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2025年12月29日 (一) 11:47的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7" >第7行：</td>
<td colspan="2" class="diff-lineno">第7行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <del class="diffchange diffchange-inline">300px</del>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <ins class="diffchange diffchange-inline">320px</ins>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td></tr>
</table>
77921020
https://www.yiliao.com/index.php?title=IDH1&diff=311612&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2025-12-29T11:44:43Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>IDH1</strong>（Isocitrate Dehydrogenase 1），全称为 <strong>异柠檬酸脱氢酶 1</strong>，编码一种定位于细胞质和过氧化物酶体的关键代谢酶。在正常生理下，IDH1 催化异柠檬酸氧化脱羧生成 <strong>[[α-酮戊二酸]]</strong> (α-KG)，同时产生 NADPH，参与细胞抗氧化防御。然而，当 IDH1 发生特定的<strong>错义突变</strong>（如 <strong>R132</strong> 位点）时，酶的功能发生根本性改变，获得产生致癌代谢物 <strong>[[2-羟基戊二酸]]</strong> (2-HG) 的新能力。2-HG 能够抑制多种表观遗传修饰酶，导致全基因组 DNA 高甲基化，从而阻断细胞分化并促进肿瘤发生。IDH1 突变是低级别<strong>[[胶质瘤]]</strong>的定义性特征，也是急性髓系白血病和胆管癌的重要治疗靶点。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 300px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">IDH1 · 基因档案</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Gene & Protein Profile (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<br />
[[文件:Protein_IDH1_Dimer_PDB.png|100px|IDH1 二聚体结构 (PDB 1T0L)]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">NADP+ 依赖性代谢酶</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc; width: 40%;">基因符号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;"><strong>IDH1</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">基因全名</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">Isocitrate Dehydrogenase (NADP(+)) 1</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">常用别名</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">IDH, IDP, PICD</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">染色体位置</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">2q34</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">Entrez</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">3417</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">HGNC</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">5382</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">OMIM</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">147700</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">UniProt</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">O75874</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">酶学分类</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">氧化还原酶 (EC 1.1.1.42)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; color: #475569; background-color: #f8fafc;">分子量</th><br />
<td style="padding: 8px 12px; color: #0f172a;">~46 kDa</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：代谢重编程与表观遗传异常</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
IDH1 的致癌机制是代谢与表观遗传学交叉的经典范例。突变主要发生在催化活性位点的精氨酸残基（<strong>R132</strong>），这种突变并非简单的功能丧失，而是赋予了酶一种新的“<strong>获得性功能</strong>”（Neomorphic Activity）。<br />
</p><br />
<br />
<br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>致癌代谢物 2-HG：</strong> 突变型 IDH1 将正常的产物 α-酮戊二酸 (α-KG) 进一步还原为 <strong>(R)-2-羟基戊二酸 (2-HG)</strong>。2-HG 的结构与 α-KG 极其相似，充当了 α-KG 依赖性双加氧酶的竞争性抑制剂。</li><br />
<li style="margin-bottom: 12px;"><strong>表观遗传沉默：</strong> 2-HG 强力抑制 <strong>[[TET酶]]</strong>（DNA 去甲基化酶）和 JmjC 组蛋白去甲基化酶。这导致全基因组 DNA 出现高甲基化表型（<strong>G-CIMP</strong>），沉默关键的分化基因，将细胞锁定在未分化的干细胞样状态。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床景观：预后良好的“钻石突变”</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
有趣的是，虽然 IDH1 突变驱动了肿瘤发生，但在胶质瘤中，它却是一个强有力的<strong>预后良好</strong>标志物，这可能与肿瘤生长缓慢及对放化疗更敏感有关。<br />
</p><br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 90%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">癌种类型</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">突变频率/位点</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床意义</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">弥漫性胶质瘤 (LGG / GBM)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>>80%</strong> (低级别)<br>R132H 最常见</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">2021 WHO 分类定义性特征。IDH 突变型胶质瘤生存期显著长于 IDH 野生型。1p/19q 共缺失状态进一步细分少突胶质细胞瘤。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">急性髓系白血病 (AML)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">~6-10%<br>R132C/H</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">常发生于正常核型 AML，随年龄增长频率增加。是艾伏尼布（Ivosidenib）的直接靶点。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">肝内胆管癌 (ICC)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">~15-20%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">不吸烟、非肝炎患者中更常见。靶向治疗可显著延缓疾病进展。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">软骨肉瘤</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">~50%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">包括 IDH1 和 IDH2 突变，是该类肿瘤最常见的分子异常之一。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">靶向治疗：分化诱导剂</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
针对 IDH1 突变的小分子抑制剂不仅能降低 2-HG 水平，还能解除分化阻滞，诱导肿瘤细胞分化为正常细胞，而非直接杀伤，这一机制与维甲酸治疗 APL 类似。<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[艾伏尼布]] (Ivosidenib/AG-120)：</strong> 首个获批的口服、强效 IDH1 突变特异性抑制剂。<br />
<br><span style="font-size: 0.9em; color: #64748b;">*适应症：复发/难治性 AML、新诊断的不适合化疗的 AML、局部晚期或转移性胆管癌。</span><br />
</li><br />
<li style="margin-bottom: 12px;"><strong>[[Vorasidenib]] (AG-881)：</strong> 具有高血脑屏障穿透率的新一代双重（IDH1/2）抑制剂。INDIGO 研究显示其能显著延缓低级别胶质瘤的进展，有望改变胶质瘤治疗格局。</li><br />
<li style="margin-bottom: 12px;"><strong>分化综合征 (Differentiation Syndrome)：</strong> 治疗过程中需警惕的一种特殊副作用，由大量白血病细胞突然分化引起，表现为发热、呼吸困难等，需皮质类固醇处理。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键关联概念</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>2-羟基戊二酸 (2-HG)：</strong> IDH 突变产生的致癌代谢物（Oncometabolite），是诊断和疗效监测的生物标志物。</li><br />
<li style="margin-bottom: 12px;"><strong>G-CIMP 表型：</strong> 胶质瘤 CpG 岛甲基化表型，由 2-HG 抑制 TET 酶引起，是 IDH 突变胶质瘤的表观遗传特征。</li><br />
<li style="margin-bottom: 12px;"><strong>IDH2：</strong> IDH1 的同工酶，定位于线粒体，突变常见于 AML，但极少见于胶质瘤。</li><br />
<li style="margin-bottom: 12px;"><strong>1p/19q 共缺失：</strong> 与 IDH 突变共同定义少突胶质细胞瘤的分子特征。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Parsons DW, et al. (2008).</strong> <em>An integrated genomic analysis of human glioblastoma multiforme.</em> <strong>Science</strong>. <br><br />
<span style="color: #475569;">[学术点评]：具有里程碑意义的发现。通过全基因组测序意外在胶质母细胞瘤中发现了 IDH1 突变，彻底改变了脑胶质瘤的分子分型。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Dang L, et al. (2009).</strong> <em>Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.</em> <strong>Nature</strong>. <br><br />
<span style="color: #475569;">[学术点评]：揭示了 IDH1 突变的生化本质，首次鉴定出 2-HG 这种致癌代谢物，连接了代谢与表观遗传学。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>DiNardo CD, et al. (2018).</strong> <em>Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.</em> <strong>New England Journal of Medicine</strong>. <br><br />
<span style="color: #475569;">[学术点评]：证实了艾伏尼布单药治疗复发难治性 AML 的安全性和有效性，促成了药物获批。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[4] <strong>Mellinghoff IK, et al. (2023).</strong> <em>Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.</em> <strong>New England Journal of Medicine</strong>. <br><br />
<span style="color: #475569;">[学术点评]：INDIGO 研究。显示 Vorasidenib 能显著延缓低级别胶质瘤的进展，是脑胶质瘤靶向治疗的重大突破。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[5] <strong>Abou-Alfa GK, et al. (2020).</strong> <em>Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.</em> <strong>The Lancet Oncology</strong>. <br><br />
<span style="color: #475569;">[学术点评]：确立了艾伏尼布在晚期胆管癌中的治疗地位，是胆管癌精准治疗的重要进展。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1.5px solid #0f172a; border-radius: 8px; overflow: hidden; font-size: 0.95em;"><br />
<div style="background-color: #0f172a; color: #ffffff; text-align: center; font-weight: bold; padding: 10px; letter-spacing: 1px;">IDH1 · 知识图谱关联</div><br />
<div style="padding: 15px; background: #ffffff; line-height: 2.2; text-align: center; text-decoration: none;"><br />
[[胶质瘤]] • [[急性髓系白血病]] • [[2-羟基戊二酸]] • [[艾伏尼布]] • [[表观遗传]] • [[Vorasidenib]] • [[IDH2]] • [[胆管癌]]<br />
</div><br />
</div><br />
<br />
</div></div>
77921020